Omeros Corporation focuses on developing first-in-class therapeutics for both large-market and orphan indications. The company's lead commercial product, YARTEMLEA (narsoplimab), is an FDA-approved complement inhibitor targeting the lectin pathway's effector enzyme MASP-2 for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Its clinical pipeline includes OMS1029, a long-acting MASP-2 inhibitor, and OMS527, a phosphodiesterase 7 (PDE7) inhibitor being evaluated for cocaine use disorder. In 2025, Omeros entered into a major asset purchase and license agreement with Novo Nordisk for its MASP-3 inhibitor zaltenibart. The company leverages its proprietary drug discovery platforms to advance treatments for conditions with high unmet medical needs.
